Cargando…

Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group

Detalles Bibliográficos
Autores principales:	Amoaku, Winfried M., Ghanchi, Faruque, Bailey, Clare, Banerjee, Sanjiv, Banerjee, Somnath, Downey, Louise, Gale, Richard, Hamilton, Robin, Khunti, Kamlesh, Posner, Esther, Quhill, Fahd, Robinson, Stephen, Setty, Roopa, Sim, Dawn, Varma, Deepali, Mehta, Hemal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608436/ https://www.ncbi.nlm.nih.gov/pubmed/32699378 http://dx.doi.org/10.1038/s41433-020-1087-6

Ejemplares similares

Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series
por: Ahmed, Muna, et al.
Publicado: (2020)

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF
por: Zou, Di, et al.
Publicado: (2021)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta, Hemal, et al.
Publicado: (2020)

Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery
por: Amoaku, Winfried, et al.
Publicado: (2020)

The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
por: Pearce, Ian, et al.
Publicado: (2022)

Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedema
por: Pearce, Ian, et al.
Publicado: (2019)

Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease
por: Gale, R, et al.
Publicado: (2017)

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy (EMERALD)
por: Lois, Noemi, et al.
Publicado: (2019)

Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)

Diabetic Macular Oedema Guidelines: An Australian Perspective
por: Yuen, Yew Sen, et al.
Publicado: (2023)

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)

Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2021)

Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial
por: Lois, Noemi, et al.
Publicado: (2019)

Real-Life ILUVIEN (Fluocinolone Acetonide) Case Study: Rapid Drying of the Macula and Improved Vision within 2 Years after Therapy Initiation
por: Quhill, Hibba, et al.
Publicado: (2016)

Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era
por: Downey, Louise, et al.
Publicado: (2021)

Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population
por: Braimah, Imoro Zeba, et al.
Publicado: (2022)

Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London
por: Dinah, Christiana, et al.
Publicado: (2021)

Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
por: Talks, S. James, et al.
Publicado: (2019)

Cataract surgery in diabetes mellitus: A systematic review
por: Kelkar, Aditya, et al.
Publicado: (2018)

Correction: Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London
por: Dinah, Christiana, et al.
Publicado: (2021)

CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA
por: Chakravarthy, Usha, et al.
Publicado: (2018)

Factors Influencing Response to Aflibercept in Diabetic Macular Oedema Patients in a Diverse North West London Population: A Real-World Study
por: Sim, Sing Yue, et al.
Publicado: (2021)

Successful Use of Intravitreal Bevacizumab and Pascal Laser Photocoagulation in the Management of Adult Coats’ Disease
por: Raoof, Naz, et al.
Publicado: (2013)

Indicators of Visual Prognosis in Diabetic Macular Oedema
por: Sen, Sagnik, et al.
Publicado: (2021)

Siponimod-related bilateral cystoid macular oedema and intravenous fluorescein angiographic findings in a patient with stable proliferative diabetic retinopathy without history of diabetic macular oedema
por: Foos, William F, et al.
Publicado: (2022)

Diabetes and the COVID-19 pandemic
por: Khunti, Kamlesh, et al.
Publicado: (2022)

Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia
por: Khunti, Sachin, et al.
Publicado: (2019)

Prevalence and associated risk factors of diabetic retinopathy and macular oedema in patients recently diagnosed with type 2 diabetes
por: Graue-Hernandez, Enrique O, et al.
Publicado: (2020)

Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
por: Romero-Aroca, Pedro, et al.
Publicado: (2016)

Risk of Diabetes Following COVID-19: Translating Evidence Into Clinical and Public Health Actions
por: Zaccardi, Francesco, et al.
Publicado: (2022)

Healthy lifestyle choices and microvascular complications: New insights into diabetes management
por: Chudasama, Yogini V., et al.
Publicado: (2023)

Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema
por: Cornish, Elisa E, et al.
Publicado: (2023)

Insulin Oedema in Newly Diagnosed Type 1 Diabetes Mellitus
por: Baş, Veysel Nijat, et al.
Publicado: (2010)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Impact of metabolic control on macular thickness in diabetic macular oedema
por: Peng, Yi-Jie, et al.
Publicado: (2017)

Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema
por: Mateos-Olivares, Milagros, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g5r0p3ptdrja2m8gk27jbp7sde